02772nas a2200397   4500000000100000008004100001260002200042653002700064653002400091100002100115700002300136700002200159700001600181700001400197700001200211700001300223700001300236700001400249700001100263700001100274700001400285700001400299700002100313700001500334700001200349700001200361700001700373700002100390700001700411245018400428856007000612300002000682490000600702520164100708022002502349       2022                            d  bSAGE Publications10aPharmacology (medical)10aInfectious Diseases1 aFranco-Paredes C1 aGarcia-Creighton E1 aHenao-Martínez A1 aKallgren DL1 aBanjade R1 aDyer JA1 aNelson T1 aZaesim A1 aPeluso MJ1 aJain V1 aLee DH1 aMinces LR1 aWirshup M1 aSierra Hoffman M1 aKatsolis J1 aBrust K1 aGiron J1 aSmiarowski L1 aHoosepian-Mer PA1 aStryjewska B00aNovel approaches in the treatment of Hansen’s disease (Leprosy): a case series of multidrug therapy of monthly rifampin, moxifloxacin, and minocycline (RMM) in the United States  uhttps://journals.sagepub.com/doi/reader/10.1177/20499361221135885  a2049936122113580 v93 a<p>The World Health Organization (WHO) recommends multidrug therapy (MDT) for the treatment of paucibacillary and multibacillary forms of leprosy, also known as Hansen’s disease (HD). MDT combinations of dapsone, rifampin, and clofazimine have reduced the prevalence of the disease but are not without adverse effects impacting regimen adherence. Hence, an urgent need exists to consider alternative MDT regimens with an improved safety profile that promotes treatment adherence. Herein, we described a case series of 10 patients with HD (nine patients with multibacillary leprosy and one with pure neural leprosy) treated with monthly rifampin, moxifloxacin, and minocycline (RMM). The United States National Hansen’s Disease Program (NHDP) diagnosed and treated patients across US institutions. All patients received a regimen of 12–24 months of RMM. We reviewed the clinical outcomes, adherence, rate of completion, and adverse events of patients treated with monthly RMM from January 2019 to August 2022. Nine patients had multibacillary leprosy, with some having type-2 reactions. One patient had pure neural leprosy with a reversal reaction. In this case series, we identified that all patients completed the RMM regimen without treatment interruptions. None of the patients experienced any skin hyperpigmentation or any significant side effects. All patients tolerated the monthly RMM regimen with rapid improvement of skin lesions and without logistic hurdles. Based on previous clinical evidence and the results of this case series, the NHDP and other programs should consider the RMM regimen as first-line therapy.</p>
  a2049-9361, 2049-937X